Results 1 to 10 of about 6,538 (235)

Benralizumab Depletes IL‐5Rα‐Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis [PDF]

Clinical and Translational Allergy
Background Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by tissue eosinophilia and itch. We evaluated the effect of eosinophil depletion with benralizumab on markers of inflammation in the skin of patients with AD.
Christiane E. Whetstone, Ruth P. Cusack, Emma L. Price, Karen J. Howie, Caitlin Stevens, Dhuha Al‐Sajee, Suzanne Beaudin, Jennifer Wattie, Nadia Alsaji, Abbey Schlatman, Vanessa Luk, Paul M. O'Byrne, Mark D. Inman, Roma Sehmi, Hermenio Lima, Gail M. Gauvreau   +15 more
doaj   +5 more sources

Long-term effectiveness and safety of benralizumab in EGPA: a 3-year single-center experience [PDF]

Annals of Medicine
Objectives Benralizumab emerged as a promising treatment option for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the long-term effectiveness and safety of benralizumab in patients with severe asthma and relapsing-refractory ...
Federica Davanzo, Luca Iorio, Marta Codirenzi, Eleonora Fiorin, Gabriella Guarnieri, Alessia Achille, Fulvia Chieco Bianchi, Maria Rita Marchi, Andrea Vianello, Andrea Doria, Roberto Padoan   +10 more
doaj   +3 more sources

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts [PDF]

Allergy, Asthma & Clinical Immunology, 2021
Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian, Jane Jiyoon Park, Michael W. Tsoulis, Harold Kim   +3 more
doaj   +2 more sources

Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma [PDF]

Biomolecules, 2023
Benralizumab treatment reduces exacerbations and improves symptom control and quality of life in patients with severe eosinophilic asthma. However, the determination of biomarkers that predict therapeutic effectiveness is required for precision medicine.
Yuuki Sandhu, Norihiro Harada, Hitoshi Sasano, Sonoko Harada, Shoko Ueda, Tomohito Takeshige, Yuki Tanabe, Ayako Ishimori, Kei Matsuno, Sumiko Abe, Tetsutaro Nagaoka, Jun Ito, Asako Chiba, Hisaya Akiba, Ryo Atsuta, Kenji Izuhara, Sachiko Miyake, Kazuhisa Takahashi   +17 more
doaj   +2 more sources

Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma.

PLoS ONE, 2021
PurposeTo characterize the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab in terms of forced expiratory volume in 1 second (FEV1) improvement.Patients and methodsSixty-four participants diagnosed with ...
Hideyasu Yamada, Masayuki Nakajima, Masashi Matsuyama, Yuko Morishima, Naoki Arai, Norihito Hida, Taisuke Nakaizumi, Hironori Masuko, Yohei Yatagai, Takefumi Saito, Nobuyuki Hizawa   +10 more
doaj   +2 more sources

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series

Journal of Asthma and Allergy, 2021
Francesco Menzella,1 Marco Bonavia,2 Matteo Bonini,3 Maria D’Amato,4 Salvatore Lombardo,5 Nicola Murgia,6 Vincenzo Patella,7,8 Massimo Triggiani,9 Girolamo Pelaia10 1Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia-IRCCS,
Menzella F, Bonavia M, Bonini M, D'Amato M, Lombardo S, Murgia N, Patella V, Triggiani M, Pelaia G   +8 more
doaj   +3 more sources

Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab [PDF]

ACR Open Rheumatology
Objective In the phase 3 head‐to‐head MANDARA study (NCT04157348), benralizumab demonstrated noninferiority to mepolizumab in inducing remission (defined as Birmingham Vasculitis Activity Score [BVAS] of 0 and oral glucocorticoid [OGC] dosage ≤4 mg/day ...
Michael E. Wechsler, Nancy Agmon‐Levin, David R. W. Jayne, Christian Pagnoux, Ulrich Specks, Lena Börjesson Sjö, Sofia Necander, Anat Shavit, Claire Walton, Peter A. Merkel   +9 more
doaj   +2 more sources

Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis

Frontiers in Pharmacology, 2022
Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma.
Yasuhiko Koga, Haruka Aoki-Saito, Yosuke Kamide, Makiko Sato, Hiroaki Tsurumaki, Masakiyo Yatomi, Tamotsu Ishizuka, Takeshi Hisada   +7 more
doaj   +1 more source

Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings

Фармакоэкономика, 2022
Objective: evaluation of the pharmacoeconomic feasibility of using benralizumab in the form of autoinjector (pen-injector device) in outpatient facilities compared with its use in the form of a syringe in hospital settings for the treatment of severe ...
M. V. Zhuravleva, S. N. Avdeev, Yu. V. Gagarina, T. V. Marin   +3 more
doaj   +1 more source

Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE)

Clinical and Translational Allergy, 2022
Background Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation. The effects of these compound on the immunoglobulin (Ig)E T2 component are virtually
Marco Contoli, Pierachille Santus, Francesco Menzella, Cindy Rocchi, Dejan Radovanovic, Federico Baraldi, Chiara Martelli, Serena Casanova, Carlo Barbetta, Claudio Micheletto, Nicola Scichilone, Bianca Beghè, Elisiana Carpagnano, Alberto Papi   +13 more
doaj   +1 more source